Published Date: 21 Oct 2025
A surveillance study compared international cancer incidence trends of 13 cancer types in younger and older adults.
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
After all, Pulled Myeloma Drug May Help Treat the Illness.
2.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
3.
Prostate cancer early detection system eliminates need for biopsy.
4.
Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity
5.
Some low-grade prostate cancers carry higher risks than biopsy suggests
1.
AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology
2.
Gene Therapy for Hemophilia: A New Hope on the Horizon
3.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
4.
The Digital Revolution in Oncology - How Software, AI, and Data are Reshaping Cancer Care by 2025
5.
The Danger of Methemoglobinemia and How to Prevent It
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation